VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO 2021 | EV-103: enfortumab vedotin and pembrolizumab in urothelial carcinoma

Terence W. Friedlander, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, provides updates on the multicohort Phase Ib/II EV-103 trial (NCT03288545) of enfortumab vedotin and pembrolizumab in first-line locally advanced or metastatic urothelial carcinoma. In a cohort of 45 patients who were cisplatin-ineligible, 93% of patients showed tumor shrinkage with an overall response rate (ORR) was 73.3%. Dr Friedlander additionally discusses the safety profile of enfortumab vedotin and pembrolizumab treatment as well as PD-L1 as a biomarker in urothelial cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter